@rethinktestosterone's FDA claims need more context

What did @rethinktestosterone actually say?

The creator summarized recent FDA activity around testosterone labeling, citing clinical trial data. Specifically, they said trials found "no extra risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism" and that the FDA is recommending "removing language related to an increased risk" from all testosterone product labels. They also noted testosterone is approved only for men with a diagnosed medical condition causing low levels.

This is a fairly accurate summary of real regulatory movement. The creator isn't hyping a cure or pushing a product. They're relaying what amounts to a meaningful, evidence-based shift in how the FDA characterizes cardiovascular risk for this drug class. That said, the framing is optimistic in ways that deserve scrutiny.

Does the science back this up?

Yes, largely, but the picture is more complicated than "no extra risk" implies. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) is the study driving this conversation. It enrolled over 5,200 men with hypogonadism and existing or high risk of cardiovascular disease, randomizing them to testosterone or placebo. The primary endpoint, a composite of death from cardiovascular causes, nonfatal heart attack, and nonfatal stroke, showed testosterone was non-inferior to placebo.

That's meaningful. The old FDA warning came partly from a 2010 study (Basaria et al., NEJM) that was stopped early due to cardiovascular events in a much smaller, frailer population. TRAVERSE provides far stronger evidence. However, TRAVERSE also found higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. Non-inferiority on the primary endpoint doesn't mean zero risk. The creator's phrase "no extra risk" flattens those secondary findings.

What did they get wrong (or right)?

They got the headline right. The FDA is indeed recommending a label update based on TRAVERSE, and the direction of that change is toward removing the cardiovascular warning language. The FDA's own statement from 2024 confirms the agency reviewed the trial and found it did not show increased risk for major adverse cardiovascular events in this population.

What's missing is nuance. "No extra risk" is accurate for the primary composite endpoint, but TRAVERSE documented a statistically significant increase in atrial fibrillation (risk ratio approximately 1.16) and pulmonary embolism. Those aren't minor footnotes. A complete account would acknowledge that the cardiovascular picture shifted, not cleared entirely. The creator also doesn't distinguish between men with clinically confirmed hypogonadism and men pursuing testosterone for optimization without a formal diagnosis, a distinction the FDA explicitly maintains and one that matters for anyone watching this and thinking it applies to them.

What should you actually know?

The TRAVERSE trial is genuinely significant. It's the largest, longest randomized controlled trial of testosterone therapy in men with hypogonadism and cardiovascular risk, and it did not show increased rates of heart attack, stroke, or cardiovascular death compared to placebo. That's a real finding worth knowing.

But the FDA label change doesn't mean testosterone is cardiovascular risk-free. It means the specific warning about major adverse cardiac events is being reconsidered for a specific population: men with documented hypogonadism. The FDA hasn't changed its position that testosterone is not approved for age-related low testosterone without an underlying medical condition, a point the creator actually mentioned correctly.

If you're considering TRT, the conversation still needs to happen with a physician who can assess your actual testosterone levels, symptoms, and cardiovascular history. A label update is not a green light for self-directed hormone use.

• TRAVERSE trial (Lincoff et al., 2023, NEJM): primary cardiovascular endpoint was non-inferior for testosterone vs. placebo in hypogonadal men.
• Secondary findings in TRAVERSE included elevated atrial fibrillation and pulmonary embolism rates in the testosterone group.
• FDA approval remains limited to men with hypogonadism caused by a diagnosed medical condition, not lifestyle-related low testosterone.